Latest in Huntington Ingalls
Sort by
2 items
-
Huntington Ingalls' Shares Tumble on Outlook Cut, Navy Contract Delay
The biggest U.S. military shipbuilder pulled its five-year free cash-flow forecast amid uncertainty about a submarine contract, supply-chain disruption and the loss of experienced workers.Business - The Wall Street Journal - October 31 -
Sage Therapeutics to end development of key therapy after a third trial failure
It was the third failed trial for the therapy, called dalzanemdor, which also failed to meet its goals in a Phase 2 trial as a treatment for mild cognitive impairment and mild dementia in ...Business - MarketWatch - 3 days ago